August 25th 2025
Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.
Autoimmune Encephalitis: What Psychiatrists Need to Know
January 29th 2020This article broadly reviews the pathophysiology of the most common forms of autoimmune encephalitis and provides guidelines tailored toward mental health professionals to best identify and manage these rare but important causes of neuropsychiatric illness.
Read More
Infectious Burden and Alzheimer Disease: Is There a Link?
It is crucial for practicing psychiatrists to consider that Alzheimer disease can be aggravated by infections of different origin.
Read More
Clinical Characteristics of Chronic Traumatic Encephalopathy
August 29th 2019The collective awareness of this devastating neurodegenerative disease will likely result in intensifying efforts to improve our understanding of disease pathology as well as exploring potentially a promising therapeutic regimen.
Read More
The aim of this article is to show that tinnitus is secondary to an aberrant brain-ear circuitry affected by disorders such as mood, anxiety, and alcohol and substance abuse as well as executive dysfunction, migraine, sleep and stress. By treating these comorbidities, tinnitus tends to improve.
Read More
Addressing Psychogenic Nonepileptic Seizures: Clinical Challenges
July 30th 2019DSM-5 categorizes PNES as a functional neurological disorder or conversion disorder with seizures. It is essential that neurologists, psychiatrists, and other clinicians coordinate care to ensure that patients with PNES receive a prompt diagnosis.
Read More